Boston (Press Release) - Acetylon Pharma­ceu­ticals, Inc., the leader in the devel­op­ment of selective histone deacetylase (HDAC) inhibitors for en­hanced thera­peutic out­comes, today announced that its selective HDAC inhibitor drug can­di­dates will be the subject of eleven presentations, in­­clud­ing three oral presentations and eight poster presentations of pre­clin­i­cal and clin­i­cal research in multiple myeloma, lym­phoma and sickle cell disease/β-thalassemia at the American Society of Hematology (ASH) Annual Meeting to be held De­cem­ber 7-10, 2013, in New Orleans, LA. The presentations will in­clude interim updates of two clin­i­cal trials of ACY-1215, a selective HDAC6 inhibitor: a Phase 1/2 trial in com­bi­na­tion with bor­tez­o­mib and dexa­metha­sone and a Phase 1b trial in com­bi­na­tion with lena­lido­mide and dexa­metha­sone for the treat­ment of re­lapsed or refractory multiple myeloma. In addi­tion, Acetylon and scientific col­lab­o­rators will present results of pre­clin­i­cal studies of ACY-1215, demonstrating potent com­bi­na­tion treat­ment in disease models of mul­ti­ple mye­lo­ma and lym­phoma, along with pre­clin­i­cal studies of its selective HDAC1/2 inhibitors in sickle cell dis­ease and β-thalassemia.

Details of the presentations are as follows:

About Acetylon

Acetylon Pharma­ceu­ticals, Inc., based in Boston, Massachusetts, is a leader in the devel­op­ment of novel small molecule drugs targeting epigenetic mech­a­nisms for the en­hancement of thera­peutic out­comes in cancer and other critical human diseases. The Company’s epigenetic drug discovery plat­form has yielded a pro­pri­e­tary portfolio of optimized, orally-administered Class I and Class II histone deacetylase (HDAC) selective com­pounds. Alteration of HDAC reg­u­la­tion through selective HDAC inhibition is thought to be appli­­cable to a broad range of diseases in­­clud­ing cancer, sickle cell disease and beta-thalassemia, and auto­immune and neurodegenerative diseases. Acetylon’s lead drug can­di­date, ACY-1215, is a selective HDAC6 inhibitor cur­rently in Phase 1b clin­i­cal devel­op­ment for the treat­ment of multiple myeloma. The Company recently announced a strategic col­lab­o­ration agree­ment with Celgene Corpo­ra­tion, which in­cludes an exclusive option for the future acquisition of Acetylon by Celgene. Acetylon’s scientific founders are affiliated with the Harvard University, the Dana-Farber Cancer Institute, the Massachusetts General Hospital, the Broad Institute and Harvard Medical School. www.acetylon.com

Source: Acetylon Pharma­ceu­ticals.